Avipro™ 104 MG Bacterin

Indications

• Prevention of bacterial infections
• Active immunization against specific bacterial pathogens
• Veterinary use for livestock and pets

Dosage

Children: Refer to specific product guidelines for dosage information, as bacterins vary by formulation.

Adults: Refer to specific product guidelines for dosage information, as bacterins vary by formulation.

Mechanism of action

Bacterins work by exposing the immune system to inactivated bacteria, which promotes the activation of immune cells, such as B cells and T cells. This leads to the production of specific antibodies that can recognize and neutralize the target bacteria upon subsequent exposures. The immune memory established through vaccination enables the body to mount a quicker and more effective response to future infections caused by the same pathogens.

Pharmacodynamics

The pharmacodynamics of bacterins involve the stimulation of the humoral immune response. Upon administration, the inactivated bacteria are processed by antigen-presenting cells, leading to the activation of helper T cells and the subsequent activation of B cells. The B cells differentiate into plasma cells that secrete antibodies, facilitating opsonization and phagocytosis of the bacteria. This process not only protects against the specific bacterial infections but also enhances the overall immune competence of the host.

Pharmacokinetics

Bacterins are typically administered via intramuscular or subcutaneous injection. Following administration, they are taken up by immune cells at the injection site and transported to lymph nodes, where the immune response is initiated. The persistence of immune response varies depending on the formulation and the specific bacterin used, but generally, the immunological memory can last for months to years, requiring booster doses to maintain immunity over time.

Pregnancy

Bacterins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is recommended.

Breast-feeding

The safety of bacterins during breastfeeding has not been established. Caution is advised.

Storage

Bacterins should be stored according to the manufacturer's instructions, typically in a cool, dry place, away from direct sunlight, and at the temperature recommended for stability.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Bacterial infections in poultry
• Respiratory infections
• Enteritis
• Bacterial pneumonia

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Adults: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Mechanism of action

Gallisepticum works by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. This action prevents the translocation of peptides and halts the growth of bacteria, making it bacteriostatic. Its selectivity for bacterial ribosomes over mammalian ribosomes contributes to its therapeutic efficacy and safety profile.

Pharmacodynamics

The pharmacodynamic profile of gallisepticum indicates that it is effective at low concentrations against susceptible microorganisms. The drug exhibits a time-dependent killing effect, meaning that the duration of exposure at therapeutic levels is critical for achieving optimal antibacterial activity. Resistance may develop through various mechanisms, including methylation of adenine residues in the 23S rRNA, which decreases drug binding.

Pharmacokinetics

Gallisepticum is well absorbed from the gastrointestinal tract when administered orally. It undergoes extensive metabolism in the liver, with a significant first-pass effect. The elimination half-life varies depending on the species but generally ranges from several hours to a day. The drug is primarily excreted through bile and urine, with a minor fraction excreted unchanged. Its distribution in tissues is wide, allowing effective penetration into respiratory tissues.

Pregnancy

There is limited data on the use of gallisepticum during pregnancy. It is advisable to use caution and consult with a healthcare provider.

Breast-feeding

There is insufficient information regarding the excretion of gallisepticum in human milk. Caution is recommended if administered during breastfeeding.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Primary adrenal insufficiency (Addison's disease)
• Congenital adrenal hyperplasia
• Orthostatic hypotension
• Heart failure
• Hypertension associated with hyperaldosteronism

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations based on age and weight.

Adults: Refer to specific guidelines in the BNF for adequate dosing. Dosing should be individualized based on the condition being treated and patient response.

Mechanism of action

Mineralocorticoids exert their effects by binding to mineralocorticoid receptors (MR) in target tissues such as the kidneys, colon, and heart. This binding leads to the activation of genes responsible for sodium reabsorption, potassium secretion, and water retention, ultimately resulting in increased blood volume and blood pressure.

Pharmacodynamics

The pharmacodynamic effects of mineralocorticoids include increased renal tubular reabsorption of sodium and increased urinary excretion of potassium. These actions lead to fluid retention and increased blood pressure. Additionally, they have roles in electrolyte balance and the regulation of cardiovascular function.

Pharmacokinetics

Mineralocorticoids are typically administered orally or intravenously and are well absorbed from the gastrointestinal tract. They have variable half-lives depending on the specific compound used. The metabolism occurs primarily in the liver, and elimination is predominantly via renal excretion. The pharmacokinetics can be affected by various drug interactions, as seen with certain medications that alter their metabolism or clearance.

Interactions

• cobicistat+mineralocorticoidreceptorantagonists: Severe (increases exposure)
• dabrafenib+mineralocorticoidreceptorantagonists: Severe (decreases exposure)
• bosentan+mineralocorticoidreceptorantagonists: Severe (decreases exposure)
• idelalisib+mineralocorticoidreceptorantagonists: Severe (increases exposure)
• clarithromycin+mineralocorticoidreceptorantagonists: Severe (increases exposure)
• mitotane+mineralocorticoidreceptorantagonists: Severe (decreases exposure)
• rifampicin+mineralocorticoidreceptorantagonists: Severe (decreases exposure)
• stjohn’swort+mineralocorticoidreceptorantagonists: Severe (decreases exposure)
• cenobamate+mineralocorticoidreceptorantagonists: Moderate (decreases exposure)
• amiodarone+mineralocorticoidreceptorantagonists: Unknown (increases exposure)

Pregnancy

null

Breast-feeding

null

Storage

null

Indications

• Used as a surfactant in pharmaceutical formulations
• Serves as an emulsifying agent in food and cosmetic products
• Utilized in drug delivery systems to enhance bioavailability

Dosage

Children: For pediatric dosing, consult appropriate pediatric pharmacology references or guidelines, as specific dosages are not established.

Adults: For specific dosages, refer to the relevant pharmaceutical guidelines or formulations as there is no standard dosing information available.

Mechanism of action

Monooleate acts primarily as a surfactant, reducing surface tension in aqueous environments. It promotes the formation of lipid bilayers and vesicles, enhancing the solubility and bioavailability of poorly soluble drugs. By creating a stable environment for drug molecules, monooleate assists in the transport of therapeutic agents across biological membranes, facilitating absorption and distribution.

Pharmacodynamics

The pharmacodynamic effects of monooleate are largely attributed to its role as a surfactant and emulsifier. It helps in the formation and stabilization of emulsions, enhancing the delivery of various active pharmaceutical ingredients. Its ability to modify membrane permeability can influence the pharmacological activity of co-administered drugs, potentially enhancing their therapeutic effects.

Pharmacokinetics

Monooleate is generally well-absorbed when administered orally or through other routes. It is metabolized by lipases into free fatty acids and glycerol. The absorption and distribution of monooleate can be influenced by the formulation in which it is used, as well as the presence of other ingredients. Its elimination half-life can vary depending on the route of administration and the specific formulation.

Pregnancy

There is limited information on the use of monooleate during pregnancy. Use with caution and consult healthcare professionals.

Breast-feeding

Limited data on the excretion of monooleate in breast milk. Caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Mycoplasma pneumonia
• Mycoplasma genitalium infections
• Chronic respiratory infections
• Atypical pneumonia

Dosage

Children: Refer to specific antibiotic guidelines for appropriate dosing regimens based on the infection type.

Adults: Refer to specific antibiotic guidelines for appropriate dosing regimens based on the infection type.

Mechanism of action

Mycoplasma species do not have a traditional cell wall, which makes them resistant to antibiotics that target bacterial cell wall synthesis, such as penicillins. Instead, they utilize plasma membranes that contain sterols for structural integrity. Their pathogenic mechanisms often involve adherence to host cells, evasion of the immune response, and the ability to disrupt host cell functions.

Pharmacodynamics

Mycoplasma infections can lead to a range of clinical manifestations depending on the species and the host's immune response. The presence of mycoplasma can cause inflammation and damage to respiratory epithelial cells, leading to symptoms such as cough, fever, and difficulty breathing. The immune response to mycoplasma can also contribute to the severity of the disease, as inflammation may exacerbate symptoms.

Pharmacokinetics

Due to their small size and unique structure, Mycoplasma can penetrate host tissues easily. The pharmacokinetics of treatments for mycoplasma infections depend on the specific antibiotic used, as mycoplasma are generally resistant to many standard antibiotics. Antibiotics that are effective against mycoplasma include macrolides, tetracyclines, and fluoroquinolones, which target protein synthesis or DNA replication.

Adverse effects

• Headache
• Dizziness
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Rash

Precautions

• Use with caution in patients with a history of hypersensitivity reactions.
• Monitor for potential allergic reactions during treatment.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

Consult a healthcare provider before use, as safety is not well established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Emulsifying agent in drug formulations
• Stabilizer for parenteral preparations
• Solubilizer for hydrophobic drug compounds
• Ingredient in topical formulations

Dosage

Children: Refer to specific product guidelines, as dosing varies based on formulation and intended use.

Adults: Refer to specific product guidelines, as dosing varies based on formulation and intended use.

Mechanism of action

Polysorbate functions primarily as an emulsifying agent. It reduces the surface tension between immiscible liquids, allowing them to mix more easily. This property is particularly useful in stabilizing emulsions and suspensions, facilitating the delivery of active pharmaceutical ingredients in various formulations.

Pharmacodynamics

Polysorbate does not exert pharmacological effects in the traditional sense, as it does not bind to specific receptors to elicit a physiological response. Instead, it plays a crucial role in modifying the physical properties of drug formulations, thereby enhancing drug delivery and absorption. Its ability to solubilize drugs enhances their bioavailability, particularly for poorly soluble compounds.

Pharmacokinetics

Polysorbate is generally considered to be non-toxic and is not absorbed to a significant extent when administered orally. It is metabolized by the liver and excreted primarily through the gastrointestinal tract. The pharmacokinetic profile may vary depending on the route of administration and the specific formulation in which it is used.

Adverse effects

• Allergic reactions
• Skin irritation
• Gastrointestinal disturbances

Precautions

• Use cautiously in patients with known allergies to polysorbates or related compounds
• Monitor for allergic reactions in susceptible individuals

Pregnancy

Polysorbate is generally considered safe for use during pregnancy, but consult with a healthcare provider for specific cases.

Breast-feeding

Polysorbate is considered safe during breastfeeding, but consult with a healthcare provider for individual advice.

Storage

Store at room temperature, away from direct sunlight and moisture.

Formulations

• Polysorbate 20
• Polysorbate 80

Indications

• Emulsifying agent in topical formulations
• Stabilizing agent in oral drug formulations
• Food industry applications as an emulsifier
• Cosmetic formulations

Dosage

Children: Refer to specific formulation guidelines for dosage recommendations.

Adults: Refer to specific formulation guidelines for dosage recommendations.

Mechanism of action

Sorbitan acts primarily as a surfactant and emulsifier. Its amphiphilic nature allows it to reduce the surface tension between oil and water, thereby facilitating the formation and stabilization of emulsions. The hydrophilic part of the sorbitan molecule interacts with water, while the lipophilic part interacts with oils, promoting the mixing of immiscible liquids.

Pharmacodynamics

As an emulsifier, sorbitan enhances the bioavailability of lipophilic drugs by aiding their dispersion in aqueous environments. This property is particularly valuable in formulations where uniform distribution of active ingredients is critical for efficacy. Sorbitan may also impact the release profiles of drugs from emulsified formulations, potentially affecting the onset of action.

Pharmacokinetics

Sorbitan is generally considered to be poorly absorbed when administered orally, leading to minimal systemic exposure. Its primary role is local, serving as an excipient in formulations rather than as an active therapeutic agent. Due to its emulsifying properties, it may enhance the solubility and absorption of other drugs in the gastrointestinal tract, but the absorption characteristics of sorbitan itself are limited. Metabolism and excretion details specific to sorbitan are not well-documented, as it typically functions in a non-systemic capacity.

Pregnancy

Sorbitan has not been well studied in pregnant women. Use during pregnancy should be based on a risk-benefit assessment.

Breast-feeding

Sorbitan is generally considered safe during breastfeeding, however, there is limited data available.

Storage

Store at room temperature, away from moisture and heat. Keep container tightly closed.

Formulations

• Sorbitan monooleate
• Sorbitan monostearate
• Sorbitan tristearate